Abstract:

Objective To compare the application eff ects of transcatheter arterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC) in the treatment of primary liver cancer patients. Method 80 patients with primary liver cancer admitted to Guangzhou General Hospital of China Life Insurance from January 2023 to January 2024 were selected and randomly divided into two groups, with 40 patients in each group, using a random number table method. The control group was treated with HAIC, while the observation group was treated with TACE. Compare the clinical treatment effi cacy, tumor markers, liver function indicators, and safety between two groups. Result The total eff ective rate of the observation group was 95.00% (38/40), which was higher than that of the control group [80.00%(32/40)], and the diff erence was signifi cant(P ＜ 0.05). Before treatment, there was no signifi cant diff erence in the levels of tumor markers and liver function indicators between the two groups of patients(P ＞ 0.05); After treatment, the serum carcinoembryonic antigen of the observation group patients was (8.17±1.23)μg/L, carbohydrate antigen 125 was (23.45±3.52)U/ml, aspartate aminotransferase was (51.66±5.24)U/L, alanine aminotransferase was (69.36±7.22)U/L, and total bilirubin was (15.79±2.67)μmol/L, which were significantly lower than those of the control group [(9.65±1.14)μg/L, (28.97±3.29)U/ml, (62.70±6.35)U/L, (78.95±9.13)U/L, (19.45±3.06)μmol/L, respectively], and the diff erences were signifi cant (P ＜ 0.05). There was no signifi cant diff erence in the incidence of complications between the two groups of patients (P ＞ 0.05). Conclusion Compared with HAIC, TACE treatment for primary liver cancer can achieve better effi cacy, reduce tumor markers, improve liver function, and has high safety.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, Hepatic artery infusion chemotherapy, Eff ect